CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 10 No. 10
The Paulino Article Reviewed 

Current Issues in the Diagnosis and Management of Wilms' Tumor

By Patrick Thomas, MB, BS, FACR, Temple University School of Medicine, Philadelphia | October 1, 1996

Dr. Paulino has written an excellent review of our present knowledge of Wilms' tumor. Not everyone would agree, however, that ultrasound has replaced the intravenous pyelogram (IVP). The National Wilms' Tumor Study Group (NWTSG) recommends IVP together with real-time ultrasonography as the preoperative imaging studies for the abdomen.[1] The former is used to establish the presence of a functioning opposite kidney and of any congenital abnormality. The latter identifies the presence and status of inferior vena cava thrombi.

As neither CT nor MRI can determine, with certainty, the status of the opposite kidney, the NWTSG still calls for its mobilization at laparotomy, as Dr. Paulino notes. He appropriately points out that those who advocate eliminating exploration of the opposite kidney[2,3] base their recommendation on data from a very small numbers of patients, compared with the NWTSG data. The NWTSG, therefore, continues to recommend mobilization of the opposite kidney based on the accuracy and lack of morbidity of this procedure.

National Wilms' Tumor Study 4

As the results of the third National Wilms' Tumor Study (NWTS 3) were very good (see the author's Table 2), NWTS 4 (1985 to 1994) was designed to attempt to simplify and shorten treatment for those considered at low risk, while intensifying treatment for those at high risk. Although, in NWTS 3, the addition of cyclophosphamide(Drug information on cyclophosphamide) (Cytoxan, Neosar) to vincristine, dactinomycin(Drug information on dactinomycin) (actinomycin D [Cosmegan]), and doxorubicin(Drug information on doxorubicin) achieved better results in patients with stages I to IV anaplastic Wilms' tumor, the numbers were uneven due to weighing of the randomization (21 patients receiving three drugs and 12 patients receiving four drugs), and it was felt appropriate to continue the randomization into NWTS 4.

For the remainder of the patients (excluding those with rhabdoid tumor of the kidney, who are not included in NWTS 4), the trial aimed to answer two questions: (1) Is pulse-intensive therapy (ie, a single dose of dactinomycin and doxorubicin for patients with stage III or IV, favorable histology and clear cell sarcoma) more effective than standard therapy (5 days of dactinomycin and 3 days of doxorubicin)? (2) What is the optimal duration of therapy (6 vs 15 months)? This issue of therapy duration was tested in all patients except those with stage I, favorable histology and anaplastic tumors.

A simplified version of the schema of NWTS 4 is shown in Figure 1. The results, which have been partly published in abstract form, suggest that 2-year survival rates are equivalent with the pulse-intensive and standard regimens,[4] and that toxicity (particularly hematologic) is less severe for most patients on the pulse-intensive arm.[5]

A recent analysis of NWTS 4 has also shown no demonstrable differences between the 6- and 15-month courses of therapy.[unpublished data, NWTS 4]

Patients with anaplastic tumors (stages II-IV) derived a benefit from the addition of cyclophosphamide to dactinomycin, vincristine, and doxorubicin if the tumor histology showed a diffuse pattern. No benefit could be discerned for focal anaplasia, however.[6]

National Wilms' Tumor Study 5

In NWTS 5, which began enrollment in 1995, there are no randomizations. The outline is shown in Table 1, and the radiotherapy regimens are detailed in Table 2. A major objective of the protocol is to determine the prognostic significance of the loss of heterozygosity of chromosomes 16q and 1p. This stems from an analysis of 232 patients from NWTS 3 and 4 showing that overall and relapse-free survival at 2 years was significantly worse for those with the 16q abnormality and was marginally so for those with the 1p abnormality.[7]

Also, as Dr. Paulino discusses, there is evidence that stage I patients under 2 years of age with tumors weighing less than 550 g may not need further therapy. In NWTS 1, 2, and 3, there were no differences in disease-free or overall survival in these patients regardless of the therapy employed.[8] In NWTS 5, therefore, these patients will be treated by nephrectomy only.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.



Arnold C. Paulino, MD


1. D'Angio GJ, Rosenberg H, Sharples K, et al: Position paper: Imaging methods for primary renal tumors of childhood: Costs versus benefits. Med Pediatr Oncol 21:205-212, 1993.

2. Koo AS, Koyle MA, Hurwitz RS, et al: The necessity of contralateral surgical exploration in Wilms' tumor with modern non-invasive imaging technique: A reassessment. J Urol 144:416-417, 1990.

3. Goleta Dy A, Shaw PJ, Stevens MM: Re: The necessity of contralateral surgical exploration in Wilms' tumor with modern non-invasive imaging technique: A reassessment (letter). J Urol 174:171, 1992.

4. Green DM, Breslow N, Beckwith JB, et al: A comparison between single dose and divided dose administration of dactinomycin and doxorubicin: a report from the National Wilms' Tumor Study Group (abstract). Proc Am Soc Clin Oncol 15:457, 1996.

5. Green DM, Breslow, NE, Evans I, et al: Effect of does intensity of chemotherapy on the hematological toxicity of the treatment of Wilms tumor. A report from the National Wilms Tumor Study. Am J Pediatr Hematol Oncol 16:207-212, 1994.

6. Green DM, Beckwith JB, Breslow NE, et al: Treatment of children with stages II to IV anaplastic Wilms' tumor: A report from the National Wilms' Tumor Study Group. J Clin Oncol 12:2126-2131, 1994.

7. Grundy PE, Tezerow PE, Breslow NE, et al: Loss of heterozygosity for chromosomes 16q and 1p in Wilms' Tumors predicts an adverse outcome. Cancer 54:2331-2333, 1994.

8. Green DM, Breslow NE, Beckwith JB, et al: Treatment outcomes in patients less than 2 years of age with small, stage 1, favorable-histology Wilms' tumor: A report from the National Wilms' Tumor Study. J Clin Oncol 11:91-95, 1993.



 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

A 52-Year-Old Man Presents With an Erythematous Lesion
Cesar Moran, MD , May 22, 2013

A 52-year-old man presented with an erythematous lesion in the axilla of unknown duration. Surgical excision was performed. What is your diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access
Judy Capko,  May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril
Marion K. Jenkins,  May 21, 2013
Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Finding Physician Work-Life Balance in the Small Moments
Jennifer Frank, MD,  May 21, 2013
At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs.
Three Areas to Reduce Costs at Your Medical Practice
Greg Mertz,  May 19, 2013
By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog
Michael Woo-Ming, MD,  May 18, 2013
Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • The ABCDEs of Moles and Melanomas
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Colorectal Cancer Treatments and Therapy Innovations
  • A 52-Year-Old Man Presents With an Erythematous Lesion
  • Bone Metastases
  • Palliative Radiotherapy in Elderly Patients With Bone Metastases Improves Quality of Life
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Preventing Exposure to Hazardous Drugs
  • Conflicts of Interest in Medicine: What About Ties to Payers?
  • Planning Treatment for Women With Recurrent Epithelial Ovarian Cancer
  • Preventing Exposure to Hazardous Drugs
  • Cancer Metabolism as a Therapeutic Target
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy